Abbott plans to separate nutrition business into independent public company
ABT•Abbott plans to separate its global Nutrition business into an independent, publicly traded company by the end of 2027. The new company is expected to have about $8.5 billion in annual sales, while Abbott’s remaining business is expected to have about $42 billion.
1. Planned separation
Abbott plans to separate its global Nutrition business into an independent, publicly traded company by the end of 2027. Existing shareholders will receive shares in the new company and retain ownership in both businesses. Daniel Salvadori will lead the Nutrition company as CEO.
2. Business figures
The Nutrition company is expected to have approximately $8.5 billion in annual sales and include brands such as Similac and Ensure. Abbott’s remaining business, focused on medical devices, diagnostics and established medicines, is expected to have approximately $42 billion in sales.
